Overall, this analysis demonstrates several AD risk genes are regulated either by Apoer2 and/or by the Apoer2-ICD, implicating Apoer2 and its alternative splicing in AD pathogenesis and suggesting the Apoer2/Reelin pathway is a rational target for possible AD therapies. This evidence concerns the gene RELN and Alzheimer disease.